NVS
NOVARTIS AG
NYSE: NVS · Basel, V8 · Healthcare
$151.12-5.15 (-3.30%)Closed
Market Cap$288.36B
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$118.20 – $163.64
Avg Volume1.9M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$151.12+42.8%
Pipeline

Drug candidates sponsored by NOVARTIS · ClinicalTrials.gov

91 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Famciclovir
Recurrent Genital Herpes (RGH)
Completed
2005-06past
1
Phase 4valsartan
Hypertension
Completed
2007-01past
1
Phase 4Nateglinide
Type 2 Diabetes
Completed
2007-08past
1
Phase 4Formoterol fumerate
Acute Bronchial Obstruction, Asthma
Completed
2008-09past
1
Phase 4Aldesleukin
Metastatic Renal Cell Carcinoma+1 more
Completed
2010-03-28past
1
Phase 4Emulsion, Cell Culture-based, influenza HA vaccine H1N1
Swine-Origin Influenza A H1N1 Virus
Completed
2010-04past
1
Phase 4Aliskiren
Essential Hypertension+2 more
Completed
2011-01past
5
Phase 4Valsartan/Amlodipine
Hypertension
Completed
2011-04past
1
Phase 4omalizumab
Asthma
Completed
2011-12past
1
Phase 4Rivastigmine transdermal
Alzheimer's Disease
Completed
2012-01past
1
Phase 4ENA713
Alzheimer's Dementia
Completed
2015-06past
1
Phase 4ICL670
Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Completed
2015-10past
1
Phase 4Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension
Open-Angle Glaucoma+1 more
Completed
2015-12past
1
Phase 4QVA149
Chronic Obstructive Pulmonary Disease+1 more
Completed
2016-06-26past
2
Phase 4Secukinumab
Psoriasis+1 more
Completed
2021-11-30past
1
Phase 4Asciminib
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Completed
2026-03-18past
1
Phase 4Rivastigmine, memantine
Alzheimer's Disease
Completed—1
Phase 3VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE
Hypertension
Completed
2005-03past
1
Phase 3Diclofenac Topical Sodium Gel 1%
Osteearthritis
Completed
2005-08past
1
Phase 3EC-MPS
Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS
Completed
2006-06past
1
Phase 3Valsartan 160 mg capsules
Essential Hypertension
Completed
2007-11past
1
Phase 3Enteric-coated mycophenolate sodium (EC-MPS)
Kidney Diseases
Completed
2008-06past
1
Phase 3Indacaterol 150 μg
Chronic Obstructive Pulmonary Disease
Completed
2008-07past
1
Phase 3diclofenac diethylamine gel 2.32%
Grade I/II Ankle Sprain
Completed
2009-12past
1
Phase 3vildagliptin
Diabetes Mellitus, Type 2+1 more
Completed
2011-04past
4
Phase 3IFF flavor 316 282, Paracetamol, Pseudoephedrine
Upper Respiratory Infections
Completed
2012-05past
1
Phase 3Placebo
Post-menopausal Osteoporosis
Completed
2013-04past
1
Phase 3Exemestane
Metastatic Breast Cancer
Completed
2013-11past
1
Phase 3Ranibizumab
Visual Impairment+2 more
Completed
2014-01past
1
Phase 3Nilotinib
CHRONIC MYELOGENOUS LEUKEMIA
Completed
2015-07past
1
Phase 3Canakinumab
Systemic Juvenile Idiopathic Arthritis
Completed
2017-03-07past
1
Phase 3Experimental : Secukinumab low dose
Chronic Severe Plaque-type Psoriasis
Completed
2018-12-13past
1
Phase 3Secukinumab/Adalimumab-Biosimilar
Axial Spondyloarthritis
Completed
2022-02-04past
1
Phase 2[18F]CTT1057
Prostatic Neoplasms+1 more
Completed
2023-11-24past
1
Phase 3LOU064
Chronic Spontaneous Urticaria
Completed
2024-04-25past
1
Phase 3Inclisiran
Acute Coronary Syndrome
Completed
2024-08-07past
1
Phase 3AAA817
Prostate Cancer
Recruiting
2028-09-29
1
Phase 3Remibrutinib
Chronic Pruritus of Unknown Origin
Recruiting
2029-02-26
1
Phase 3Rivastigmine
Cognitive Symptoms
Terminated—1
Phase 3Tegaserod
Dyspepsia+1 more
Completed—2
Phase 2LDE225B
Basal Cell Carcinoma
Withdrawn—1
Phase 2MenACWY-CRM Vaccine
Prevention of Meningococcal Disease
Completed
2006-11past
1
Phase 2Zoledronic Acid
Osteogenesis Imperfecta
Completed
2007-05past
1
Phase 2H5N1 Influenza Vaccine
Prophylaxis of Avian Influenza
Completed
2007-10past
1
Phase 2Pasireotide (SOM230)
Carcinoid Tumors
Completed
2008-07past
1
Phase 2MenACWY-CRM197
Meningococcal Disease
Completed
2010-07past
1
Phase 2rMenB+OMV NZ
Meningococcal Infections
Completed
2010-07past
1
Phase 2QAV680 + Cetirizine Placebo
Allergic Rhinitis
Completed
2010-07-28past
1
Phase 2AIN457
Chronic Plaque Psoriasis
Completed
2010-09past
1
Phase 2DNK333 5 mg
Pruritus in Patients With Atopic Dermatitis
Completed
2011-07past
1
Phase 2Adjuvanted H5N1 pandemic influenza vaccine
Pandemic H5N1 Influenza
Completed
2013-06past
1
Phase 2panobinostat
Relapsed and Bortezomib Refractory Multiple Myeloma+2 more
Completed
2014-02past
1
Phase 2Midostaurin (PKC412)
Leukemia
Completed
2014-12-01past
1
Phase 1BYL719
PIK3CA Mutated Advanced Solid Tumors+1 more
Terminated
2014-12-26past
1
Phase 2QGE031
Chronic Spontaneous Urticaria
Completed
2016-11-02past
1
Phase 2Dabrafenib
Cancer+1 more
Completed
2018-02-23past
1
Phase 2Fevipiprant
Asthma
Terminated
2019-12-16past
1
Phase 2CMK389
Atopic Dermatitis
Completed
2022-07-14past
1
Phase 2CFZ533
Hidradenitis Suppurativa
Completed
2024-12-04past
1
Phase 2TIN816
Acute Kidney Injury Following Cardiac Surgery
Terminated
2025-03-26past
1
Phase 2rapcabtagene autoleucel
Lupus Erythematosus, Systemic+1 more
Active, not recruiting
2028-02-14
1
Phase 2ABL001/Asciminib
Chronic Myeloid Leukemia (CML)
Recruiting
2029-02-17
1
Phase 1Patupilone
Advanced Malignancies+1 more
Completed
2006-11past
1
Phase 1LBH589
Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
Completed
2008-06past
1
Phase 1Indacaterol maleate
Asthma
Completed
2008-09past
1
Phase 1ABP688
Depression
Completed
2010-05past
1
Phase 1everolimus (RAD001)
Breast Neoplasms+1 more
Completed
2010-06past
1
Phase 1Typherix
Typhoid Fever
Completed
2010-06past
1
Phase 1Everolimus
Hepatic Insufficiency
Completed
2010-11past
1
Phase 1LBH589 (i.v. panobinostat)
Prostate Cancer
Completed
2011-12past
1
Phase 1osilodrostat
Renal Impairment
Completed
2016-03-21past
1
Phase 1BCL201
Follicular Lymphoma, Mantle Cell Lymphoma
Completed
2018-07-10past
1
Phase 1LXH254
NSCLC+3 more
Terminated
2022-02-18past
1
Phase 1VAY736
Chronic Lymphocytic Leukemia (CLL)
Terminated
2023-09-29past
1
Phase 1Licarbazepine
Healthy
Completed—1
N/AIndacaterol (Onbrez®) /QAB149
Chronic Obstructive Pulmonary Disease
Completed
2013-12past
1
N/AUnnamed
Malaria
Completed
2015-09-30past
1
N/AUnnamed
Refractive Error
Completed
2016-12-02past
1
N/AMidostaurin
Acute Myeloid Leukemia (AML)
Completed
2021-01-26past
1
N/ALucentis
Neovascular (Wet) Age-related Macular Degeneration
Completed
2021-03-31past
1
N/AUnnamed
BRAF v600 Mutated Metastatic Melanoma
Completed
2022-03-28past
1
N/AUnnamed
Melanoma
Completed
2022-11-20past
1
N/AEndocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Completed
2022-12-01past
1
N/AUnnamed
Spinal Muscular Atrophy
Completed
2022-12-30past
1
N/AUnnamed
Multiple Sclerosis
Completed
2023-02-15past
1
N/AUnnamed
Somatostatin Receptor-positive Neuroendocrine Tumor
Completed
2024-06-27past
1
N/AUnnamed
Hidradenitis Suppurativa (HS)
Recruiting
2026-09-30past
1
N/AUnnamed
Cardiovascular Diseases+2 more
Recruiting
2026-10-30
1
N/AUnnamed
Metastatic Castration Resistant Prostate Cancer
Recruiting
2029-03-30
1
N/AUnnamed
Chronic Spontaneous Urticaria
Recruiting
2029-05-31
1
N/ALCZ696
Heart Failure With Reduced Ejection Fraction (HF-rEF)
No Longer Available—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for NVS. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.